Synthetic biology company Asimov has launched its new LV edge packaging system, which it claims will improve the cost efficiency and reduce the supply chain risk of lentiviral production.
France’s Polyplus has made two acquisitions of late, one to expand its plasmid DNA engineering technology and services portfolio, and another to enhance its GMP fill and finish capacities.
Charles River recently announced the expansion of its plasmid DNA and viral vector development and manufacturing capabilities in Europe; it says the move is to support the growing need of customers and to safeguard future supply.
Polyplus, a provider of transfection reagents, has acquired e-Zyvec, a France-based provider of DNA design and production services for tailor-made DNA vectors to expand expertise in plasmid DNA vector engineering.
Andelyn Biosciences says the FDA's acceptance of its GMP plasmid DNA drug master file (DMF) enables the CDMO to vertically integrate its clients’ manufacturing process, condensing timelines for developers to begin manufacturing to just three months....
This month saw BioCina officially open its new biologics manufacturing facility in Adelaide, Australia, flagging it as the only TGA, EMA, Health Canada and US-FDA approved commercial facility of its kind in the country.
To further support the increasing number of pharma companies investing in microbials, Lonza is expanding its microbial development laboratories at its Visp, Switzerland site by 50%.
Touchlight, a synthetic DNA producer, says it has received the first phase of planning approval for breaking ground on its new research and manufacturing facility in Hampton, UK.
VGXI, Inc, a provider of plasmid DNA manufacturing and development services, says multiple construction milestones have been reached for its new headquarters and manufacturing facility in Texas.
Synthetic DNA vector producer, Touchlight, has announced the extension of its fundraising round to a current aggregate total of US$125m (£92m). The financing was led by Bridford Investments Limited and Novator Partners.
AGC Biologics is expanding its Heidelberg facility to create new capacity for messenger RNA (mRNA) projects, and to boost its plasmid-DNA (pDNA) manufacturing capabilities.
Charles River Laboratories International Inc is to acquire US based Vigene Biosciences, a cell and gene therapy (CGT) contract development and manufacturing organization (CDMO) providing viral vector-based gene delivery solutions for research and clinical...
